

# Evaluation of the diagnostic efficacy of manganese chloride tetrahydrate (CMC-001©) in magnetic resonance cholangiography in patients with suspected liver lesions: a randomised, parallel group, open-label phase II trial

<b>Submission date</b> 30/04/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/06/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 19/10/2021	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Lars Vedin

**Contact details**  
Lars Vedin AB  
Floragatan 13  
Stockholm  
Sweden  
SE-114 75  
+ 46 (0)8 5064 5751  
lv@cmc-contrast.se

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

CMC-P005

## **Study information**

### **Scientific Title**

Evaluation of the diagnostic efficacy of manganese chloride tetrahydrate (CMC-001©) in magnetic resonance cholangiography in patients with suspected liver lesions: a randomised, parallel group, open-label phase II trial

### **Study objectives**

The primary objective is to assess the efficacy and the time-response of manganese chloride tetrahydrate (CMC-001©) in two dose levels as a contrast medium in Magnetic Resonance (MR)-cholangiography and to further evaluate the safety and tolerability of CMC-001© in patients.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approval received from the regional ethical committee in Gothenburg on the 7th September 2006 (ref: 235-06).

### **Study design**

This study is an open label, parallel group, randomised, single centre study in patients with suspected liver lesions.

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Diagnostic

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Magnetic resonance imaging of the liver, bile ducts and the gall bladder.

### **Interventions**

Patients with suspected liver lesions will be given either a full dose (1.6 g) or half dose (0.8 g) of CMC-001©. A total of 16 fully evaluable patients will be included, 8 patients in each treatment arm. The study will be conducted at one site in Sweden.

Each patient will visit the clinic on three occasions:

1. The screening visit
2. For Magnetic Resonance Imaging (MRI)
3. For a follow-up

In addition, a telephone follow-up will be performed 48 hours after administration of CMC-001©. The total study duration for each patient is not more than 10 days. The patients are assessed by MRI at pre-dose and 2.5 and 4 hours post dose.

Every patient will have three visits to the clinic at screening when MRI is done and blood samples for laboratory analyses is done, at the treatment day when two MRIs are done at 2.5 hours and 4 hours after contrast. The third occasion is a visit to the clinic 24 hours after contrast for safety reasons with new blood samples for laboratory testing is drawn. All patients will also be contacted by telephone 48 hrs after contrast when Adverse Events (AEs) will be asked for.

## **Intervention Type**

Drug

## **Phase**

Phase II

## **Drug/device/biological/vaccine name(s)**

Manganese chloride tetrahydrate (CMC-001©)

## **Primary outcome measure**

The primary objective is to assess the efficacy and the time-response of CMC-001© in two dose levels as a contrast medium in MR-cholangiography and to further evaluate the safety and tolerability of CMC-001© in patients.

## **Secondary outcome measures**

1. To assess if CMC-001©-enhanced MR-cholangiography provides an equally good or improved image quality of the non-dilated biliary tree in comparison to T2-weighted MR cholangiography
2. To assess and compare the visualisation and delineation of focal liver lesions before contrast and after 2.5 and 4 hours after administration of CMC-001©
3. To assess the extent to which the pancreatic duct is filled 2.5 and 4 hours post administration of CMC-001©

## **Overall study start date**

01/05/2006

## **Completion date**

31/12/2007

# **Eligibility**

## **Key inclusion criteria**

1. Men or women over 18 years old
2. Patients that are referred for MR imaging of the liver for suspected liver pathologies indicated by ultra-sound or Computed Tomography (CT) meriting further investigation
3. Signed written informed consent
4. The patients are conscious and co-operative

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

16

**Key exclusion criteria**

1. Medical history or abnormal physical findings which could interfere with the safety or objectives of the study as judged by the investigator
2. Clinically relevant haematology, clinical chemistry, serology and urine chemistry abnormalities, based on the judgement of the investigator
3. Concomitant diseases which can interfere with gastrointestinal absorption, e.g., malabsorption, gastrectomy, Irritable Bowel Disease (IBD) or major surgical interventions in the Gastrointestinal (GI) tract
4. Patients who has undergone papillotomy
5. Patients who have MR contraindications according to the hospital checklist, e.g., pacemaker
6. One or more tumour greater than 10 cm, or several tumours greater than 5 cm, as judged by ultra-sound or CT
7. Allergy to any of the study product ingredients
8. Drug or alcohol abuse
9. Participation in another clinical study concerning pharmaceuticals
10. Previous inclusion in this study
11. Pregnancy (checked at visit two by pregnancy test when relevant)
12. Patients scheduled to receive contrast medium intravascularly within two days before inclusion or within three days after the CMC-001© administration
13. Patients with newly discovered unstable diabetes or undergoing haemodialysis or peritoneal dialysis
14. Known Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
15. Confirmed or suspected acute hepatitis
16. Bilirubin less than 40 µmol/l
17. Sepsis
18. The patient has a non-compensated cardiac failure (cardiac failure New York Heart

Association [NYHA] grade four)

19. Patients who are deemed to be unsuitable for any other reason in the opinion of the investigator

**Date of first enrolment**

01/05/2006

**Date of final enrolment**

31/12/2007

## **Locations**

**Countries of recruitment**

Sweden

**Study participating centre**

**Lars Vedin AB**

Stockholm

Sweden

SE-114 75

## **Sponsor information**

**Organisation**

Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

**Sponsor details**

c/o Lars Vedin AB

Floragatan 13

Stockholm

Sweden

SE-114 75

+ 46 (0)8 5064 5751

lv@cmc-contrast.se

**Sponsor type**

Industry

**Website**

<http://www.cmc-contrast.se>

**ROR**

<https://ror.org/015x46y72>

# **Funder(s)**

## **Funder type**

Industry

## **Funder Name**

Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)

# **Results and Publications**

## **Publication and dissemination plan**

Not provided at time of registration

## **Intention to publish date**

## **Individual participant data (IPD) sharing plan**

## **IPD sharing plan summary**

Not provided at time of registration